Solodyn and Pregnancy
Links shared publicly online about this topic
USPTO awards Medicis new patent for SOLODYN Extended Release Tablets
news-medical.net — “Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.” View full resource at news-medical.net
Most Recently Shared on September 8, 2010 at 1:11 pm By:
Pregnancy News: USPTO awards Medicis new patent for SOLODYN Extended Release Tablets: Medicis today announced that... http://bit.ly/bT0mUC
FDA approves additional strengths of SOLODYN for inflammatory lesions treatment
news-medical.net — “Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.” View full resource at news-medical.net
Most Recently Shared on August 30, 2010 at 5:35 pm By:
Pregnancy News: FDA approves additional strengths of SOLODYN for inflammatory lesions treatment: Medicis today ann... http://bit.ly/a30UnM
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Pregnancy news and research via News-Medical.Net
-
News-Medical.Net
Stay up to date with the latest Pregnancy news and research via News-Medical.Net
Advertisement
